MyDosage · Personal evidence dossier

Weight loss

Incretin and dual-agonist peptides — appetite, weight, and glycemic control.

DSR-WEIG-20260820

Issued August 20, 2026

Editorial · independent

01Top candidate

Semaglutide

GLP-1 receptor agonist · t½ ~7 days

Long-acting GLP-1 analogue approved for type-2 diabetes and chronic weight management. The most rigorously studied peptide on this index.

Evidence Intelligence Score™

8.0/ 10Strong

Strongest

4 indexed clinical studies across 3 outcomes; signal currently reads moderate.

Weakest

Effect sizes outside trial populations and durations beyond the studied window remain less characterized.

Unknowns

Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.

Outlook

Outlook: tracked. The score above re-grades automatically as new indexed evidence is admitted.

02Ranked candidates

03Safety register